Skip to content
SPEVIGO® (Spesolimab-sbzo) | HCP
  • Important Safety Information
  • Full Prescribing Information
  • Medication Guide
  • Patient Site
  • Request a Rep
  • Understanding GPP
    • What Is GPP?
    • What Causes GPP Inflammation?
  • SPEVIGO in Action
    • Targeting IL-36 (MOA)
    • Dosing and Administration
    • Ongoing Trials
  • SPEVIGO (IV)
    • Proven Efficacy With IV
    • Proven Safety With IV
  • SPEVIGO (SC)
    • Proven Efficacy With SC
    • Proven Safety With SC
  • Access and Resources
    • Getting Patients Started
    • Patient Support
    • Video Hub
    • Infusion Site Locator

FOR US HEALTHCARE PROFESSIONALS

Contact Us
  • Understanding GPP
    • What Is GPP?
    • What Causes GPP Inflammation?
  • SPEVIGO in Action
    • Targeting IL-36 (MOA)
    • Dosing and Administration
    • Ongoing Trials
  • SPEVIGO (IV)
    • Proven Efficacy With IV
    • Proven Safety With IV
  • SPEVIGO (SC)
    • Proven Efficacy With SC
    • Proven Safety With SC
  • Access and Resources
    • Getting Patients Started
    • Patient Support
    • Video Hub
    • Infusion Site Locator

For US Healthcare Professionals

SPEVIGO® (Spesolimab-sbzo) | HCP
  • Important Safety Information
  • Full Prescribing Information
  • Medication Guide
  • Patient Site
  • Request a Rep
Contact Us

  • What Is GPP?
  • What Causes GPP Inflammation?

  • Targeting IL-36 (MOA)
  • Dosing and Administration
  • Ongoing Trials

  • Proven Efficacy With IV
  • Proven Safety With IV

  • Proven Efficacy With SC
  • Proven Safety With SC

  • Getting Patients Started
  • Patient Support
  • Video Hub
  • Infusion Site Locator

SC Results

Read More

Indication

SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg (88 lb).

Important Safety Information

Contraindications

  • SPEVIGO is contraindicated in patients with severe or life-threatening hypersensitivity to spesolimab-sbzo or to any of the excipients in SPEVIGO. Reported hypersensitivity reactions have included drug reaction with eosinophilia and systemic symptoms (DRESS) and anaphylaxis. If a patient develops mild or moderate hypersensitivity during an intravenous infusion or other infusion-related reactions, stop SPEVIGO infusion and consider appropriate medical therapy (eg, systemic antihistamines and/or corticosteroids). Upon resolution of the reaction, the infusion may be restarted at a slower infusion rate with gradual increase to complete the infusion.

Warnings and Precautions

  • Infections: SPEVIGO may increase the risk of infections. In patients with a chronic infection or a history of recurrent infection, consider the potential risks and expected clinical benefits of treatment prior to prescribing SPEVIGO. Treatment with SPEVIGO is not recommended in patients with any clinically important active infection until the infection resolves or is adequately treated. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur during or after treatment with SPEVIGO. If a patient develops a clinically important active infection, discontinue SPEVIGO therapy until the infection resolves or is adequately treated.
  • Risk of Tuberculosis: Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SPEVIGO. Avoid use of SPEVIGO in patients with active TB infection. Consider initiating anti-TB therapy prior to initiating SPEVIGO in patients with latent TB or a history of TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SPEVIGO treatment.
  • Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions, including anaphylaxis and delayed reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during and following administration of SPEVIGO. These reactions can occur with the first dose or subsequent doses.
  • Vaccinations: Prior to initiating SPEVIGO for treatment of GPP, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients during and for at least 16 weeks after treatment with SPEVIGO. No specific studies have been conducted in SPEVIGO-treated patients who have recently received live viral or live bacterial vaccines.

Adverse Reactions

  • The most common adverse reactions with SPEVIGO when experiencing a flare include asthenia and fatigue, headache, nausea, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
  • The most common adverse reactions with SPEVIGO when not experiencing a flare include injection site reaction, urinary tract infection, arthralgia, and pruritus.

Please see full Prescribing Information (opens in a new tab), including Medication Guide (opens in a new tab) and Instructions for Use (opens in a new tab).

SPEVIGO® (Spesolimab-sbzo) | HCP
  • About LEO Pharma Inc.
  • Contact Us
  • Privacy Policy
  • Your Privacy Choices
  • Terms of Use

Information for Colorado Prescribers

Follow Us

  • YouTube
  • Facebook
  • LinkedIn

The LEO Pharma logo and SPEVIGO® are registered trademarks of LEO Pharma A/S.
© 2026 LEO Pharma Inc. All rights reserved.
MAT-97836 November 2026

LEO Pharma

Please confirm

This website may not be intended for visitors in your location. Please confirm to continue

Deny

You are about to leave SPEVIGOhcp.com

Leave site (opens in a new tab)
LEO Pharma LTDA

Av. Engenheiro Luís Carlos Berrini, 1645 - 7 floor
ZIP 04571-011 São Paulo
Brazil

(+55 ) 11 0800 779 7799
www.leo-pharma.com.br

LEO Pharma Inc.

6 Adelaide Street East, Suite 200
M5C 1H6 Toronto, ON
Canada

(+1) 905 886 9822
www.leo-pharma.ca

LEO Pharmaceuticals, S. de R. L. de C.V.

Blvd. Adolfo Ruiz Cortines # 3642 Piso 7 Col. Jardines del Pedregal
C.P. 01900 Mexico D.F.
Mexico

(+52) 55 3684 7400
latinoamerica.leo-pharma.com

LEO Pharma Inc.

7 Giralda Farms, 2nd Floor
NJ 07940 Madison
United States of America

(+1) 877 494 4536
www.leo-pharma.us

LEO Pharma Consultancy (Shanghai) Company Limited

No. 378-386, South Wulumuqi Road No. 1172, 1F, Xuhui District
200000 Shanghai
China

(+86) 21 5407 5988
www.leo-pharma.cn/

LEO Pharma K.K.

Jinbocho Mitsui Building 9F 1-105 Kanda-Jinbocho
Chiyoda-ku, 101-0051 Tokyo
Japan

(+81) 3 5809 2468
www.leo-pharma.jp

LEO Pharma Yuhan Hoesa

(Taepyeong-ro 1-ga) 7th Floor 136 Sejong-daero, Jung-gu
04520 Seoul
South Korea

(+82) 2 771 1110
www.leo-pharma.kr

LEO Pharma Ges.m.b.H.

Gertrude-Fröhlich-Sandner Straße 2-4, Turm 9, Etage 7,8,9
A-1110 Vienna
Austria

(+43) 1 503 69 79
www.leo-pharma.at
leo-pharma.at@leo-pharma.com

LEO Pharma N.V.

Duwijckstraat 17
2500 Lier
Belgium

(+32) 3 740 78 68
www.leo-pharma.be

LEO Pharma s.r.o.

Lomnického 1705/7
Praha 4 Prague
Czech Republic

(+420) 721 546 611

LEO Pharma A/S

Industriparken 55
2750 Ballerup
Denmark

(+45) 4494 5888
www.leo-pharma.com/

LEO Pharma Esbjerg

Maadevej 76
6705 Esbjerg Ø
Denmark

(+45) 4494 5888
www.leo-pharma.com/

LEO Pharma Oy

Karhumäentie 3
FI-01530 Vantaa
Finland

(+358) 20 721 8440
nordics.leo-pharma.com/

Laboratoires LEO

Immeuble Ampère E+ La Défense 34 Rue Henri Régnault 34-40
92400 Courbevoie
France

(+33) 1 30 14 40 00
www.leo-pharma.fr

LEO Pharma GmbH

Siemensstraße 5b
63263 Neu-Isenburg
Germany

(+49) 6102 201 0
www.leo-pharma.de

LEO Pharmaceutical Hellas S.A

22A Papanikoli St.
GR-152 32 Chalandri
Greece

(+30 ) 2 12 222 5000
www.leo-pharma.gr

LEO Pharma Cork (Wexport Ltd.)

Wallingstown Little Island
T45 RP82 Cork
Ireland

(+353) 21 4354102
www.leo-pharma.co.uk

LEO Pharma Ireland

285 Cashel Road
12 Dublin
Ireland

(+353) 1 490 8924
www.leo-pharma.co.uk

LEO Pharma Italia S.p.A.

Via Elio Vittorini, 129
00144 Rome
Italy

www.leo-pharma.it

LEO Pharma Manufacturing Italy S.R.L.

Via Schering 21
20054 Segrate
Italy

www.leo-pharma.it

LEO Pharma BV

Delflandlaan 1
1062EA Amsterdam
Netherlands

www.leo-pharma.nl

LEO Pharma AS

Martin Linges Vei 25
1364 Fornebu
Norway

(+47) 22 51 49 00
nordics.leo-pharma.com/

(LEO Pharma) Global Business Service Center sp. z o. o.

Skanska Wave, Aleja Grunwaldzka 347
80-309 Gdansk
Poland

www.leo-pharma.pl

LEO Pharma Sp. z o.o.

Marynarska 15
02-674 Warsaw
Poland

(+48) 22 244 18 40
www.leo-pharma.pl

LEO Farmacêuticos, Limitada

Rua do Mar da China nº 3, Piso 4ª
1990-138 Lisbon
Portugal

(+351) 217 110 760
www.leo-pharma.pt

LEO Pharmaceutical Products LLC

Leningradsky Prospekt 72 building 2
125315 Moscow
Russia

(+7) 495 789 11 60
ru.leo-pharma.com

LEO Pharma s.r.o., organizačná zložka

Karpatské námestie 10
831 06 Bratislava
Slovakia

Laboratorios LEO Pharma, SA

Via Layetana 33. 7ª Planta
08003 Barcelona
Spain

(+34) 93 221 33 66
www.leo-pharma.es

LEO Pharma AB

Hyllie Stationsväg 42, Box 404
201 24 Malmö
Sweden

(+46) 40 35 22 00
nordics.leo-pharma.com

Leo Pharmaceutical Products Sarath Ltd.

The Circle 6
CH - 8058 Zürich
Switzerland

Tel +41 43 343 75 75
www.leo-pharma.ch

LEO Laboratories Limited

Roxborough Way, Foundation Park, Building 5
SL6 3UD Maidenhead
United Kingdom

(+44) (0)1844 347 333
www.leo-pharma.co.uk

LEO Pharma A/S Arabia for Pharmaceutical Consultancy

Building No. 3605, Al Amir Sultan Ibn Abdulaziz Street, Al Sulamaniyah District P. O. Box 991
11421 Riyadh
Saudi Arabia

www.leo-pharma.sa/

LEO Pharma A/S - Rep. Office

Barsha Heights I-Rise Tower, 34 Floor, C1 & C2
P.O. Box 9952 Dubai
United Arab Emirates

(+971) (4) 2476 400

LEO Pharma Pty Ltd

Suite 3, Level 1 5 Lamington Street
New Farm Qld 4005
Australia

(+61) 7 3250 1200
www.leo-pharma.com.au

LEO Pharma Limited

Ground Floor, Carlton Gore Road, Newmarket 110
1023 Auckland
New Zealand